HCP Live March 7, 2024
Lana Pine

The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation.

The US Food and Drug Administration (FDA) has approved the tocilizumab biosimilar, tocilizumab-aazg (Tyenne), for the treatment of a variety of inflammatory and immune diseases, including rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis. The drug is the first tocilizumab biosimilar with an FDA-approved intravenous and subcutaneous formulation and marks the third biosimilar approval for Fresenius Kabi.1

“Offering the first FDA-approved tocilizumab biosimilar therapy option in both intravenous and subcutaneous formulations to people living with autoimmune diseases in the US is a moment of great pride for Fresenius Kabi,” Michael Schönhofen, Dr. rer. Nat,Fresenius Kabi President Biopharma, said in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar
The Biden Administration’s Swan Song on Digital Health: Two FDA Guidances on Artificial Intelligence and FDA’s Defense of its Clinical Decision Support Guidance
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown

Share This Article